Galenika

Galenika, founded in 1945, is a significant entity in the Pharmaceuticals and Healthcare sectors. In November 2017, it was integrated into EMS, a leading Latin American pharmaceutical company recognized globally. This acquisition positions Galenika within the NC group, a reputable pharmaceutical conglomerate, enabling it to align with emerging technological advancements in the industry. The company's strategic integration into EMS signifies a commitment to leveraging international expertise and resources to drive innovation and expand its market reach within Europe and beyond.

Operating across 3 locations, Galenika employs a workforce of 500-1,000 professionals dedicated to innovation and quality. The company specializes in a range of products including pharmaceuticals, medical supplies, dietary supplements, and generic drugs, emphasizing increased efficiency and quality in production. To understand the human capital driving these advancements, one can Meet Galenika's team. This focus on operational excellence and technological integration is key to its strategy, ensuring that its product development pipeline remains robust and responsive to market needs.

With a reported revenue of $100.1M, Galenika is committed to producing high-quality medicines and health products. Its operations adhere to principles designed to enhance patient well-being and promote healthier outcomes. The company's strategic direction involves continuous development of new technologies and maintaining high standards in its European market presence, ensuring both quantity and efficacy in its offerings. Galenika's dedication to advancing healthcare solutions underscores its role as a key player in the pharmaceutical landscape.